Close Menu

NEW YORK – Natera said after the close of the market on Wednesday that its first quarter revenues increased 41 percent over Q1 2019.

Last month, the company said it expected a 35 percent year-over-year increase in revenues for the quarter.

For the quarter ended March 31, Natera reported $94 million in revenues, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.